Literature DB >> 7032752

Human platelet phenolsulphotransferase: separate control of the two forms and activity range in depressive illness.

S M Carter, V Glover, M Sandler, P K Gillman, P K Bridges.   

Abstract

Human phenolsulphotransferase exists in two forms, one specific for dopamine and tyramine, termed "M" and one for phenol, termed "P". In this study we have shown that these two forms are under separate control by correlating their activities in different individuals using different substrates. There was a highly significant correlation between the activities with dopamine, p-tyramine and 4-hydroxy-3-methoxyphenylglycol, but no significant correlation between the activities with any of these three substrates and that with phenol. Neither age nor sex had any effect on platelet phenolsulphotransferase "M" or "P" activities. Nor was there any significant correlation between platelet monoamine oxidase activity and phenolsulphotransferase "M" or "P" activities. Human platelet phenolsulphotransferase "M" was found to be unstable at temperatures above 35 degree C and it lost substantial activity when stored deep frozen in isotonic saline. However it was stable for up to four months when stored in isotonic sucrose or 10 mmol/l phosphate buffer (pH 7.4). Phenolsulphotransferase "M" amd "P" activities were measured in platelets from depressed patients of a diagnostic type characterized by low output of tyramine-O-sulphate after oral tyramine loading but their enzyme activities were not different from those in two control groups.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7032752     DOI: 10.1016/0009-8981(81)90121-2

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  12 in total

1.  Red wine contains a potent inhibitor of phenolsulphotransferase.

Authors:  J T Littlewood; V Glover; M Sandler
Journal:  Br J Clin Pharmacol       Date:  1985-02       Impact factor: 4.335

2.  Sulphate conjugation of beta 2-adrenoceptor stimulating drugs by platelet and placental phenol sulphotransferase.

Authors:  R J Sodha; H Schneider
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

3.  High incidence of endogenous depression in migraine: confirmation by tyramine test.

Authors:  J Jarman; M Fernandez; P T Davies; V Glover; T J Steiner; C Thompson; F C Rose; M Sandler
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-07       Impact factor: 10.154

4.  Platelet phenolsulphotransferase activity in Parkinson's disease.

Authors:  V Glover; A J Lees; C Ward; G M Stern; M Sandler
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

5.  Minoxidil sulphation in human liver and platelets. A study of interindividual variability.

Authors:  G M Pacifici; R Bigotti; G Marchi; L Giuliani
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Human platelet phenolsulphotransferase M and P: substrate specificities and correlation with in vivo sulphoconjugation of paracetamol and salicylamide.

Authors:  S M Bonham Carter; G Rein; V Glover; M Sandler; J Caldwell
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

7.  Sulphate conjugation of p-hydroxytriamterene by platelet phenol sulphotransferase: assay conditions and correlation with metabolism in man.

Authors:  C Reiter; P G Werness; J Van Loon; L H Smith; R M Weinshilboum
Journal:  Br J Clin Pharmacol       Date:  1983-02       Impact factor: 4.335

8.  The human phenolsulphotransferase polymorphism is determined by the level of expression of the enzyme protein.

Authors:  A L Jones; R C Roberts; M W Coughtrie
Journal:  Biochem J       Date:  1993-12-01       Impact factor: 3.857

9.  Human platelet phenol sulfotransferase: familial variation in thermal stability of the TS form.

Authors:  J Van Loon; R M Weinshilboum
Journal:  Biochem Genet       Date:  1984-12       Impact factor: 1.890

10.  (+) and (-) terbutaline are sulphated at a higher rate in human intestine than in liver.

Authors:  G M Pacifici; M Eligi; L Giuliani
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.